A Novel Sequential Regimen of Efgartigimod and Telitacicept as Fast‐Acting Treatment for Impeding Crisis of MuSK‐MG
Immunity, Inflammation and Disease · 2026-10 · 14 (10)
DOI: 10.1002/iid3.70521 ↗Kurz gefasst
Fallbericht in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 09.10.2026. Verfasst von Tianjiao Duan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Receptor Protein-Tyrosine Kinases, Receptors, Cholinergic, Recombinant Fusion Proteins. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province, Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University.
Abstract (Originalsprache)
Background
Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction. The muscle‐specific kinase (MuSK) antibody‐positive subtype often involves bulbar and respiratory muscles, conferring a high risk of myasthenic crisis.
Method
We report a very late‐onset MuSK‐MG case complicated by lung infection and acute heart failure, with a history of peptic ulcer. The patient was sequentially treated with efgartigimod and telitacicept, achieving minimal symptom expression (MSE) within 1.5 months.
Discussion
Following the first efgartigimod infusion, QMG and MG‐ADL scores improved from 31 to 23 and 22 to 12, respectively. After five injections of telitacicept, symptoms resolved completely on day 47, with scores further reducing to 2 (QMG) and 0 (MG‐ADL). Treatment also reduced IgG levels and MuSK‐Ab titers, while IgM remained stable.
Conclusion
This case demonstrates the successful sequential use of efgartigimod and telitacicept in managing complicated, late‐onset MuSK‐MG in a state of impeding crisis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Clinical Medical Research Center for Stroke Prevention and Treatment of Hunan Province, Department of Neurology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Neurology, the Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
ORCID-Profile: Tianjiao Duan
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
- Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University
Zitieren
APA
Duan, T., Ouyang, S., Lu, W., & Yin, W. (2026). A Novel Sequential Regimen of Efgartigimod and Telitacicept as Fast‐Acting Treatment for Impeding Crisis of MuSK‐MG. Immunity, Inflammation and Disease, 14(10). https://doi.org/10.1002/iid3.70521
Vancouver
Duan T, Ouyang S, Lu W, Yin W. A Novel Sequential Regimen of Efgartigimod and Telitacicept as Fast‐Acting Treatment for Impeding Crisis of MuSK‐MG. Immunity, Inflammation and Disease. 2026;14(10). doi:10.1002/iid3.70521
BibTeX
@article{Duan2026,
author = {Duan, Tianjiao and Ouyang, Song and Lu, Wei and Yin, Weifan},
title = {A Novel Sequential Regimen of Efgartigimod and Telitacicept as Fast‐Acting Treatment for Impeding Crisis of MuSK‐MG},
journal = {Immunity, Inflammation and Disease},
year = {2026},
volume = {14},
number = {10},
doi = {10.1002/iid3.70521}
}
EUVIMED